Tripelennamine

Overview

Tripelennamine is a histamine H1 -receptor antagonist. Tripelennamine effectively reverses histamine-induced bronchoconstriction, increased transpulmonary pressure, elevated pulmonary vascular resistance and reduced dynamic compliance. Tripelennamine does not significantly affect arterial hypoxemia, hemoglobin desaturation and hypercapnia in horses undergoing short-term high-intensity exercise. Tripelennamine exhibits local and central analgesic activity. Tripelennamine can be used in studies related to emphysema, urticaria and acute laminitis.

Application

Products | Products > Disease Areas > Skin Inflammation | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Pain | Products > Disease Areas > Urticaria | Products > Disease Areas > Emphysema | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Allergy | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Histamine Receptor

Product Information

• Catalog No.: HY-17428A
• CAS No.: 91-81-6
• Molecular Formula: C16H21N3
• Molecular Weight: 255.36
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source